Trial Profile
A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Sunitinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SATURNE
- 12 Jun 2018 Status changed from active, no longer recruiting to completed.
- 27 May 2016 Planned primary completion date changed from 1 Jul 2013 to 1 Jul 2018.
- 27 May 2016 Status changed from recruiting to active, no longer recruiting.